p.89 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e202 4 Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aor tic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16:834–841. 5. Yang LT, Pellikka PA, Enriquez-Sarano M, et al. Diastolic blood pressure and heart rate are independently associated with mortality in chronic aortic re gurgitation. J Am Coll Cardiol. 2020;75:29–39. 6. Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart. 2018;104:644–651. 7. Otto CM. Heartbeat: beta-blockers for aortic regurgitation. Heart. 2016;102:165–167. 8. Aronow WS. Hypertension, aortic stenosis, and aortic regurgitation. Ann Transl Med. 2018;6:43. 9. Elder DH, Wei L, Szwejkowski BR, et al. The impact of renin-angiotensin- aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol. 2011;58:2084–2091. 5.3.7 Aortic Disease 1 Rooprai J, Boodhwani M, Beauchesne L, et al. Central hypertension in pa tients with thoracic aortic aneurysms: prevalence and association with an eurysm size and growth. Am J Hypertens. 2022;35:79–86. 2. Altobelli E, Rapacchietta L, Profeta VF, et al. Risk factors for abdominal aor tic aneurysm in population-based studies: a systematic review and metaanalysis. Int J Environ Res Public Health. 2018;15:2805. 3. Kobeissi E, Hibino M, Pan H, et al. Blood pressure, hypertension and the risk of abdominal aortic aneurysms: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2019;34:547–555. 4. Hibino M, Otaki Y, Kobeissi E, et al. Blood pressure, hypertension, and the risk of aortic dissection incidence and mortality: results from the J-SCH Study, the UK Biobank Study, and a meta-analysis of cohort studies. Circula tion. 2022;145:633–644. 5. Otaki Y, Watanabe T, Konta T, et al. Effect of hypertension on aortic artery disease-related mortality; 3.8-year nationwide community-based prospec tive cohort study. Circ J. 2018;82:2776–2782. 6. Howard DP, Banerjee A, Fairhead JF, et al. Age-specific incidence, risk fac tors and outcome of acute abdominal aortic aneurysms in a defined popula tion. Br J Surg. 2015;102:907–915. 7. Jaeger BC, Bress AP, Bundy JD, et al. Longer-term all-cause and cardiovas cular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022;7:1138–1146. 8. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small ab dominal aortic aneurysms. Br J Surg. 2012;99:655–665. 9. Isselbacher EM, Preventza O, Black JH 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the Ameri can Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146:e334–e482. 5.3.8 Hypertension Treatment in Patients With CKD 1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103– 2116. 2. Aggarwal R, Petrie B, Bala W, et al. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension. 2019;73:1275–1282. 3. Malhotra R, Nguyen HA, Benavente O, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and metaanalysis. JAMA Intern Med. 2017;177:1498–1505. 4. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network metaanalysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728–741. 5. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of reninangiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008. 6. Plantinga LC, Miller ER 3rd, Stevens LA, et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009;54:47–56. 7. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707–719.e708. 8. Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. Angiotensin-converting en zyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63:650–658. 9 Wright J, Jackson T., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431. 10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. 11. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860. 12. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. 13. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282–287. 14. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91:683–690. 15. McCallum W, Tighiouart H, Ku E, et al. Acute declines in estimated glo merular filtration rate on enalapril and mortality and cardiovascular out comes in patients with heart failure with reduced ejection fraction. Kidney Int. 2019;96:1185–1194. 16. Bhandari S, Mehta S, Khwaja A, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021–2032. 17. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892– 1903. 18. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmis artan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553. 5.3.8.1 Hypertension After Kidney Transplantation 1 Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplanta tion. Am J Kidney Dis. 2004;43:1071–1081. 2. Malhotra R, Katz R, Weiner DE, et al. Blood pressure, chronic kidney disease progression, and kidney allograft failure in kidney transplant recipients: a sec ondary analysis of the FAVORIT trial. Am J Hypertens. 2019;32:816–823. 3. Chatzikyrkou C, Schmieder RE, Schiffer M. Update on treatment of hyper tension after renal transplantation. Curr Hypertens Rep. 2021;23:25. 4. Eleftheriadis G, Naik MG, Osmanodja B, et al. Office or home versus 24hour blood pressure measurement in stable kidney transplant recipients. Nephrol Dial Transplant 2024;28:gfae076. 5. Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant. 2005;19:181–192. 6. Natale P, Palmer SC, Jaure A, et al. Blood pressure lowering for kidney transplant recipients: systematic review with network meta-analysis. J Hy pertens. 2024;42:848–855. 7. Mortensen LA, Jespersen B, Helligsoe ASL, et al. Effect of spironolac tone on kidney function in kidney transplant recipients (the SPIREN tri al): a randomized placebo-controlled clinical trial. Clin J Am Soc Nephrol. 2024;19:755–766. 5.3.9 Cerebrovascular Disease 1 Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Associa tion. Circulation. 2024;149:e347-e913. 5.3.9.1 Acute Intracerebral Hemorrhage 1 Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in pa tients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355– 2365. 2. Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pres sure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023;402:27–40. 3. Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019;18:857–864. 4. Manning L, Hirakawa Y, Arima H, et al. Blood pressure variability and out come after acute intracerebral haemorrhage: a post-hoc analysis of INTER ACT2, a randomised controlled trial. Lancet Neurol. 2014;13:364–373. 5. Arima H, Heeley E, Delcourt C, et al. Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2. Neurology. 2015;84:464– 471. Downloaded from http://ahajournals.org by on October 7, 2026